IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
News Jan 28, 2008
The Genomic Grade™ is a genomic index invented by Pr. Christos Sotiriou & Pr. Martine Piccart, from the Bordet Institute, Brussels and Dr. Mauro Delorenzi from the Swiss Institute for Cancer Research (ISREC), Lausanne, two European cancer research institutes.
In their seminal paper published in 2006 in the Journal of the National Cancer Institute, Pr. Sotiriou & colleagues showed that the grade, as measured today and since 1890 by histological examination of tumor sections under a microscope, could not describe the proliferation ability of 30 to 60 % of tumors.
By contrast, the Genomic Grade™ could capture proliferation in most tumors and showed superior prognostic & classification value over conventional grading methods. These findings have been validated in more than 1’100 patients, including a second study published last year in the Journal of Clinical Oncology.
The Genomic Grade™ represents the common core feature of the main breast cancer prognostic genomic signatures published worldwide, as shown by a meta-analysis presented by Pr. Piccart at the St. Gallen Breast Cancer conference in March 2007.
Importantly, the Genomic Grade™ can be measured by both DNA microarray and multiplex PCR technologies, as presented at the 2007 meeting of the American Society of Clinical Oncology.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.